Abstract:We herein report the synthesis, characterization, and anticancer activity of a series of iridium(III) and ruthenium(II) half-sandwich complexes of the type 6 [(Cp-x/arene)M((PO)-O-boolean AND)Cl]PF6 (M = Ir, Cp-x = pentamethylcyclopentadienyl (Cp*) or its phenyl (Cp-xPh = C5Me4C6H5) or biphenyl (Cp-xbiPh = C5Me4C6H4C6H5) derivatives; M = Ru, arene = p-cymene (p-cym); (PO)-O-boolean AND = phosphine phosphonic amide ligand (PPOA)). The X-ray crystal structures of all complexes, in which the ligand can form six-membered rings with the metal center, have been determined. All of the complexes show remarkable anticancer activities toward HeLa and A549 cancer cells, activities which are higher than that of the clinical anticancer drug cisplatin. The incorporation of phenyl substituents on the Cp* ring for iridium(III) complexes results in little variation in their anticancer activities. These results can be attributed to the combinatorial action of the metal and PPOA ligand. Hydrolysis and DNA cleavage are not the major mechanisms of action. These complexes show potent catalytic activity in the transfer hydrogenation of NADH to NAD(+). Additionally, complexes [(eta(5)-C5Me5)Ir((PO)-O-boolean AND)Cl]PF6 (1) and [(eta(6)-p-cym)Ru((PO)-O-boolean AND)Cl]PF6 (4) arrest cell cycles at S and G(2)/M phase and S phase, respectively. Complexes 1 and 4 both can induce apoptosis of HeLa cancer cells. Reactive oxygen species (ROS) and mitochondrial membrane potential tests were also performed to explore the mechanism of action. When the concentration of the complexes is increased, the amount of reactive oxygen species (ROS) increases dramatically and the mitochondrial membrane potential decreases significantly in HeLa cancer cells. Overall, cell stress including cell cycle perturbation, apoptosis induction, increase in ROS level, and loss of mitochondrial membrane potential contributes to the anticancer potency of these complexes. Interestingly, the use of confocal microscopy provides insights into the microscopic mechanism in which the typical and most active complex 1 can damage lysosomes. This type of complex represents a potent platform for development of metal anticancer drugs.

Rhodium(I) Complexes Containing the N^N^N-Chelating Ligand: Synthesis, Structure, and Biological Activity

Rhodium(III) and iridium(III) complexes with 1,2-naphthoquinone-1-oximate as a bidentate ligand: synthesis, structure, and biological activity

Synthesis of Novel NHC–Rh Complexes with Anti-Tumor Activity Against MCF-7 Human Breast Cancer Cells

16-Electron Half-Sandwich Rhodium(III), Iridium(III), and Ruthenium(II) Complexes As Lysosome-Targeted Anticancer Agents

In vitro and in vivo anticancer activity of novel Rh(III) and Pd(II) complexes with pyrazolopyrimidine derivatives

Synthesis and biological evaluation of zwitterionic half-sandwich Rhodium(III) and Ruthenium(II) organometallic complexes

Half-Sandwich Iridium(III) and Ruthenium(II) Complexes Containing P^P-Chelating Ligands: A New Class of Potent Anticancer Agents with Unusual Redox Features.

Organometallic ruthenium and iridium phosphorus complexes: Synthesis, cellular imaging, organelle targeting and anticancer applications: Organometallic Complexes Synthesis and Applications

Synthesis, Characterization, Cytotoxic Activity of Half-Sandwich Rhodium(iii), and Iridium(iii) Complexes with Curcuminoids

Half-sandwich Iridium N-heterocyclic Carbene Anticancer Complexes

Theranostic Lysosomal Targeting Anticancer and Antimetastatic Agents: Half-Sandwich Iridium(III) Rhodamine Complexes

The ruthenium complex assists in nuclear targeting and selective killing of tumor cells

Preparation of Novel Rh (III) Half-Sandwich Complexes Bearing 5-Phenyl-2-(pyridin-2-yl)-1,2-dihydro-3h-pyrazol-3-one Ligands, and Their Anti-Cancer Properties

Antitumor Activity of Iridium/ruthenium Complexes Containing Nitro -Substituted Quinoline Ligands in Vivo and in Vitro

Synthesis, Subcellular Localization and Anticancer Mechanism Studies of Unsymmetrical Iridium(III) Complexes

Potent Half-Sandwich Iridium(III) and Ruthenium(II) Anticancer Complexes Containing a P^O-Chelated Ligand

Synthesis and in Vitro Antitumor Activity of Novel Iridium(iii) Complexes with Enantiopure C2-symmetrical Vicinal Diamine Ligands

Design, Synthesis, and Evaluation of Fluorine and Naphthyridine-Based Half-Sandwich Organoiridium/ruthenium Complexes with Bioimaging and Anticancer Activity.

Enhancing Bioactivity of N,N,N-Chelating Rhodium(III) Complexes with Ionic Liquids: Toward Targeted Cancer Therapy

Lysosome-Targeted Phosphine-Imine Half-Sandwich Iridium(III) Anticancer Complexes: Synthesis, Characterization, and Biological Activity

Nickel Chloride Complexes with Substituted 4′-Phenyl-2′,2′:6′,2″-Terpyridine Ligands: Synthesis, Characterization, Anti-Proliferation Activity and Biomolecule Interactions